Linagliptin

Description: Quoth Wikipedia ever more Linagliptin INN previously known as BI1356 marketed under trade names Tradjenta US and Trajenta worldwide is a dipeptidyl peptidase4 inhibitor developed by Boehringer Ingelheim for treatment of diabetes mellitus type 2 Oncedaily linagliptin was approved by the US Food and Drug Administration FDA on 2 May 2011 for treatment of type 2 diabetes It is being marketed by Boehringer Ingelheim and Lilly Linagliptin may cause severe joint pain

By: AdamStanislav

Date: 2017-04-26

Block Explorer: View Transaction

Download

Large PNG 2400px

Medium PNG 800px

Small PNG 300px

Javascript is needed to download PNG's.


Linagliptin sourced from Openclipart is licensed under CC0 1.0

* Note: Date might not match original source and might be an educated guess.